Pricing Log in Create free account

Immatics N.V. (IMTX) vs MoonLake Immunotherapeutics (MLTX)

Immatics N.V. and MoonLake Immunotherapeutics are both Biotechnology companies. Immatics N.V. and MoonLake Immunotherapeutics are of similar size ($924.8M and $919.2M). MoonLake Immunotherapeutics has the higher net margin (0.00% vs −489.4%) and the higher return on invested capital (0.00% vs −84.8%). Across the 14 metrics below, MoonLake Immunotherapeutics leads on 8 and Immatics N.V. on 6.

Valuation

Metric IMTX MLTX Biotechnology median
P/E n/m n/m 10.60
P/S 17.61 n/m 9.40
P/B 1.87 1.98 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 12.12 n/m 9.02
Earnings yield (29.34%) (33.42%) (32.88%)
Free cash flow yield (27.74%) (26.52%) (23.13%)

Profitability

Metric IMTX MLTX Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (536.26%) 0.00% 0.00%
Net margin (489.35%) 0.00% 0.00%
Free cash flow margin (488.01%) 0.00% 0.00%
Return on equity (48.53%) (67.08%) (51.96%)
Return on assets (39.83%) (51.00%) (46.06%)
Return on invested capital (84.83%) 0.00% 0.00%

Growth

Metric IMTX MLTX Biotechnology median
Revenue growth (TTM) (64.99%) — 6.76%
EPS growth (last fiscal year) (1,313.33%) (86.77%) 29.88%
Revenue growth, 5-year CAGR 11.81% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMTX MLTX Biotechnology median
Debt to equity 0.00 0.23 0.00
Current ratio 7.54 12.56 4.97
Net debt to EBITDA 2.04 1.32 1.01

Dividend

Metric IMTX MLTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMTX MLTX Biotechnology median
Market cap 924.75m 919.15m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack